Rhenman & Partners Asset Management Ab Fibrogen Inc Transaction History

Rhenman & Partners Asset Management Ab

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$12.02 - $16.79 $2.4 Million - $3.36 Million	-200,000 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$31.0 - $55.72 $1.71 Million - $3.06 Million	55,000 Added 37.93%	200,000 $6.94 Million
Q2 2020 Jul 16, 2020	SELL	$32.57 - $42.83 $3.42 Million - $4.5 Million	-105,000 Reduced 42.0%	145,000 $5.88 Million
Q1 2020 Apr 16, 2020	SELL	$23.3 - $45.96 $582,500 - $1.15 Million	-25,000 Reduced 9.09%	250,000 $8.69 Million
Q4 2019 Jan 17, 2020	SELL	$34.58 - $48.06 $691,600 - $961,200	-20,000 Reduced 6.78%	275,000 $11.8 Million

Q3 2019 Oct 16, 2019	SELL	$36.98 - $48.45 $1.94 Million - $2.54 Million	-52,439 Reduced 15.09%	295,000 $10.9 Million
Q2 2019 Jul 22, 2019	BUY	$35.13 - $55.53 $5.55 Million - $8.77 Million	157,948 Added 83.35%	347,439 $15.7 Million
Q1 2019 Apr 11, 2019	SELL	$42.83 - $59.91 $4.81 Million - $6.72 Million	-112,236 Reduced 37.2%	189,491 $10.3 Million
Q4 2018 Feb 05, 2019	BUY	$37.97 - $60.16 $1.92 Million - $3.04 Million	50,537 Added 20.12%	301,727 $14 Million
Q3 2018 Oct 03, 2018	BUY	$56.3 - $67.25 $655,500 - $782,991	11,643 Added 4.86%	251,190 $15.3 Million
Q2 2018 Jul 20, 2018	BUY	$44.9 - $64.95 $3.14 Million - $4.55 Million	70,000 Added 41.29%	239,547 $15 Million
Q4 2017 Jan 19, 2018	BUY	$41.95 - $60.1 $1.01 Million - $1.45 Million	24,047 Added 16.53%	169,547 $8.04 Million
Q3 2017 Oct 13, 2017	BUY	$33.4 - $53.9 $4.86 Million - $7.84 Million	145,500	145,500 $7.83 Million

120

62.2M

1.54M

221K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $69.4M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Rhenman & Partners Asset Management Ab, based on Form 13F filings with the SEC.

Stay updated on Rhenman & Partners Asset Management Ab with notifications on news.